Q
Qyuns Therapeutics
HKEX-listed developer of monoclonal and bispecific antibodies for autoimmune and allergic diseases
About Qyuns Therapeutics
Qyuns Therapeutics Co., Ltd. is a clinical-stage biopharmaceutical company established in 2015, with its headquarters in Taizhou, China. The company, founded by Mr. Qiu Jiwan who also serves as the Chairman and General Manager, is focused on the research, development, and commercialization of antibody drugs for autoimmune and allergic diseases. Mr. Qiu has expressed confidence in the company's long-term value through a voluntary lock-up of his shares.
The company's business model centers on developing a pipeline of biologic therapies and then commercializing them, often through strategic partnerships with established pharmaceutical companies to maximize market reach and potential. Revenue is generated through these collaborations and from the sale of its approved products. Qyuns Therapeutics successfully listed on the Hong Kong Stock Exchange in March 2024 under the stock code 2509.HK, raising approximately $31.10 million to fund the continued development of its portfolio.
Qyuns has developed a diverse and synergistic product pipeline that covers four major disease areas: dermatology, rheumatology, respiratory, and gastroenterology. A key asset is its rabbit-based antibody discovery platform, which is noted for offering greater diversity and affinity compared to traditional mouse-based technologies. Its pipeline includes multiple candidates at various stages of clinical trials. One of its initial products, SAILEXIN® (a ustekinumab biosimilar), co-developed with Huadong Medicine, is the first of its kind approved in China for treating psoriasis. Other core products in late-stage development include QX002N for ankylosing spondylitis and QX005N for prurigo nodularis, the latter of which has received Breakthrough Therapy Designation. The company actively collaborates with partners like Hansoh Pharma and Joincare to co-develop specific drug candidates, such as QX004N for psoriasis and QX008N for severe asthma and COPD, respectively.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- 9
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Mar 2022 | $31M | $254M | TriWise Capital | — |
| SERIES BOther financing | Apr 2021 | $41M | $254M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Qyuns Therapeutics is 2.7K monthly website visits, up 58.8% over the last three months.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Qyuns Therapeutics in the Taizhou ecosystem
The Qyuns Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- HAHongtai Aplus
- TCTriWise Capital
- LFLucky Source Funds
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Qyuns Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Qyuns Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








